We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00033072
Recruitment Status : Unknown
Verified November 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : April 8, 2002
Last Update Posted : January 11, 2017
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Condition or disease Intervention/treatment Phase
Amphetamine-Related Disorders Drug: Selegiline Phase 1

Detailed Description:
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 16 participants
Allocation: Randomized
Masking: Single
Primary Purpose: Treatment
Official Title: Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline
Study Start Date : September 2001
Study Completion Date : October 2002

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. safety of selegiline
  2. pharmacokinetic assessment

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
  • Be able to verbalize understanding of consent form; provide written informed consent

Exclusion Criteria:

  • Please contact site for more information
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00033072


Locations
Layout table for location information
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00033072    
Obsolete Identifiers: NCT00024882
Other Study ID Numbers: NIDA-CTO-0004-1
First Posted: April 8, 2002    Key Record Dates
Last Update Posted: January 11, 2017
Last Verified: November 2003
Additional relevant MeSH terms:
Layout table for MeSH terms
Amphetamine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Selegiline
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
 Anti-Dyskinesia Agents
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs